

Edrecolomab

Cat. No.:	HY-P99231
CAS No.:	156586-89-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research ^{[1][2]} .									
In Vitro	<p>Edrecolomab (0-100 µg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>KATO III cells</td> </tr> <tr> <td>Concentration:</td> <td>0-100 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>20 hours</td> </tr> <tr> <td>Result:</td> <td>Exhibited an ED₅₀ value>100 ng/ml.</td> </tr> </table>		Cell Line:	KATO III cells	Concentration:	0-100 µg/mL	Incubation Time:	20 hours	Result:	Exhibited an ED ₅₀ value>100 ng/ml.
Cell Line:	KATO III cells									
Concentration:	0-100 µg/mL									
Incubation Time:	20 hours									
Result:	Exhibited an ED ₅₀ value>100 ng/ml.									
In Vivo	<p>Edrecolomab (intravenous injection; 30 µg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male nu/nu mice injected with HT-29 colon carcinoma cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30 µg/dose</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; 30 µg/dose; day 1, 4 and 7 after tumor-cell inoculation</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth with a number of significant readings (p≤0.05).</td> </tr> </table>		Animal Model:	Male nu/nu mice injected with HT-29 colon carcinoma cells ^[1]	Dosage:	30 µg/dose	Administration:	Intravenous injection; 30 µg/dose; day 1, 4 and 7 after tumor-cell inoculation	Result:	Inhibited tumor growth with a number of significant readings (p≤0.05).
Animal Model:	Male nu/nu mice injected with HT-29 colon carcinoma cells ^[1]									
Dosage:	30 µg/dose									
Administration:	Intravenous injection; 30 µg/dose; day 1, 4 and 7 after tumor-cell inoculation									
Result:	Inhibited tumor growth with a number of significant readings (p≤0.05).									

REFERENCES

[1]. Naundorf S, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer. 2002 Jul 1;100(1):101-10.

[2]. Punt CJ, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002 Aug 31;360(9334):671-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA